12:00 AM
Mar 25, 2013
 |  BC Week In Review  |  Company News  |  Other News

Dendreon cancer news

Dendreon agreed to pay $40 million to settle a securities class action lawsuit alleging the company made "materially false and misleading statements" on its finances and business operations. The statements include those on the launch and forecasts for prostate cancer therapy Provenge sipuleucel-T, Dendreon's only marketed product. The biotech's stock has taken a hit on lower-than-expected uptake of the drug, which...

Read the full 292 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >